Exploring the Therapeutic Potential of Rosemary: An In-depth Review of its Pharmacological Properties

The pharmacological effects of rosemary plant period a wide range and include anti-inflammatory and antioxidant properties. Rosemary is shown to have its potential on Ischemic stroke because of its Anti-oxidant and Anti-inflammatory properties. It contains strong antioxidants such carnosol, which has anti-inflammatory properties, and Rosmarinus acid, which fights oxidative stress. Rosemary is an attractive possibility for treating disorders like oxidative-related diseases because of its dual activity. Additionally, Rosemary has shown neuroprotective qualities that aid in maintaining brain health and cognitive function. The aromatic components in its essential oil may improve concentration and memory. Rosemary has also been investigated for its potential in hair care, with research indicating that it can encourage hair growth. These rosemary Officinalis also have different chemical substances and compounds like Terpenes, Essential oils, Bicyclic monoterpenes, Monoterpenoids, Ester and also, we have different pharmacological activates they are Anti-oxidative, Anti-inflammatory, Anti-microbial, Anti-obesity, Anti-fungal, Anti-cancer, Anti-diabetic, Cardiovascular activity, Skin health, Neuroprotective, Gastrointestinal, Sperm motility, Anti-depressant, Anti-viral activity

Glutathione and glutamate in schizophrenia: a 7T MRS study

In schizophrenia, abnormal neural metabolite concentrations may arise from cortical damage following neuroinflammatory processes implicated in acute episodes. Inflammation is associated with increased glutamate, whereas the antioxidant glutathione may protect against inflammation-induced oxidative stress. We hypothesized that patients with stable schizophrenia would exhibit a reduction in glutathione, glutamate and/or glutamine in the cerebral cortex, consistent with a postinflammatory response, and that this reduction would be most marked in patients with residual schizophrenia an early stage with positive psychotic symptoms has progressed to a late stage characterised by long-term negative symptoms and impairments. We recruited 28 patients with stable schizophrenia and 45 healthy participants matched for age, gender and parental socio-economic status. We measured glutathione, glutamate and glutamine concentrations in the anterior cingulate cortex (ACC), left insula, and visual cortex using 7T proton Magnetic Resonance Spectroscopy (MRS). Glutathione and glutamate were significantly correlated in all three voxels. Glutamine concentrations across the three voxels were significantly correlated with each other. Principal Components Analysis (PCA) produced three clear components: an ACC glutathione-glutamate component; an insula-visual glutathione-glutamate component; and a glutamine component. Patients with stable schizophrenia had significantly lower scores on the ACC glutathione-glutamate component, an effect almost entirely leveraged by the sub-group of patients with residual schizophrenia. All three metabolite concentration values in the ACC were significantly reduced in this group. These findings are consistent with the hypothesis that excito-toxicity during the acute phase of illness leads to reduced glutathione and glutamate in the residual phase of the illness